Authors: Hillegass, WB Newman, AR Raco, DL

Citation: Wb. Hillegass et al., Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes - Estimating the economic implications, PHARMACOECO, 19(1), 2001, pp. 41-55

Authors: Singh, M Reeder, GS Ohman, EM Mathew, V Hillegass, WB Anderson, RD Gallup, DS Garratt, KN Holmes, DR

Citation: M. Singh et al., Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience, J AM COL C, 38(3), 2001, pp. 624-630

Authors: Hillegass, WB Dean, NA Liao, L Rhinehart, RG Myers, PR

Citation: Wb. Hillegass et al., Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience, J AM COL C, 37(5), 2001, pp. 1335-1343

Authors: Hillegass, WB Newman, AR Raco, DL

Citation: Wb. Hillegass et al., Economic issues in glycoprotein IIb IIIa receptor therapy, AM HEART J, 138(1), 1999, pp. S24-S32